BeiGene Unveils Three ADCs To Join Global Race
Sees 'Best-In-Class' Potential
BeiGene is the latest Chinese drug maker to showcase its antibody-drug conjugate programs, including in-house discovered molecules targeting B7-H3 and CEACAM5, as well as a B7-H4-targeting ADC in-licensed from Duality Biologics.
